3. Breaking Down Barriers: An Interview with Peyton Howell

This episode features an interview with Peyton Howell discussing the evolution of patient access over the past three decades, the creation of the hub industry, and the continuing challenges faced by pharma companies and service providers in supporting patient access to medications.

Podcast: Prescription for Better Access

Episode: Ep 3

Welcome to Prescription for Better Access, a new interview-focused podcast brought to you by two healthcare industry veterans aimed to help shape the future of patient access and affordability! In this episode, co-hosts Mark Hansan and Dr. Scott Howell interview Peyton Howell, an early leader in the industry, about the evolution of patient access, the hub industry and where things are headed in terms of patient access. 

To begin, Peyton shares about her career background. She has always loved the healthcare field and worked in hospital administration to pay her way through college. While earning a Masters Degree in health administration at Ohio State University, she had the opportunity to work directly with the COO of the hospital on projects related to patient access. Thus, she was offered an early view into how to correct treatment therapies and improve patient access. After grad school she focused on the consulting side, helping hospitals and sites. She was approached by office administrators to join in on the creation of Lash Group, a practice group focused on the pharma industry.

Peyton sold Lash Group in 1998 during the early stages of her career. At AmerisourceBergen, she had the opportunity to grow the business for nearly a decade and was able to buy other access-related consulting businesses. Here, she was able to see the whole cycle of access from pharmaceutical treatments to how they work on all sides of care. Then, she was approached to work in clinical trials at Parexel, where she is now the COO. Among the major launches Peyton has played a role in, she highlights her very first one related to cystic fibrosis. She also touches on a project at Lash Group which created an explosive group and created a new model of looking holistically at patients rather than just at free drug programs.

The first launches of multiple sclerosis and rheumatoid arthritis are where the industry began to see the real challenges with payers in terms of prior authorization, certificates of medical necessity and other barriers delaying accessibility to care. This changed everything in terms of how to support patients and the new required investments of pharma companies. Looking back on her career, Peyton feels that those urgent moments are the ones she is most proud of. 20 years ago, she never would have guessed that there would be as many challenges for patients as we see today. As an industry, we need to get patients more comfortable talking about these hurdles to make people aware that they are not alone in facing them.

Payton is credited with coming up with the term “hub industry”, which is critically important for the launch of new healthcare products. It is all about efficiently removing barriers for patients and sites. Building on that, she shares her perspective on the evolution of the hub industry over the years. Today, there are so many more pieces to the puzzle and challenges to overcome than there were in decades past. Additionally, it doesn’t help that healthcare is still a very conservative industry.

Shifting gears, Peyton explains how various legislation and the government has influenced the industry overall. All of the OIG opinions that were intended to be helpful, she has found, were sometimes just more confusing for pharma companies to interpret and rely upon. We see that in the limits on the type of support pharma sponsors will typically provide. This makes the patient experience redundant, frustrating and confusing. Another major change driver has been the consolidation of major industry players, which we are seeing even more of now with vertical consolidation. Peyton’s main areas of concern are the consolidation of players and PBMs.

Next, Payton unpacks her perspective on the state of the industry today and the obstacles we are currently facing. What attracted her to clinical trials in the first place, she reveals, is the opportunity to put more of the evidence towards the next wave of breakthrough products. The only way to truly take costs out of the system is to let the data show us where it is not helping us. Before wrapping up, Peyton shares her own advice for the future of the podcast and the areas she might like to hear discussed in the future. Her desire is that things are made simple for the average family to understand how to navigate the system. Peyton, identifies the areas which make her feel hopeful about the future. The interest and awareness we are currently seeing are the major factors contributing to this hopefulness. In closing, she shares her own prescription for better access. We should all be better educated consumers for ourselves and for those patients who don’t have a voice of their own.

Timestamps:

1:14 – Introduction to today’s episode.

2:55 – Peyton’s journey in the healthcare field.

5:15 – Peyton’s time at AmerisourceBergen.

7:20 – The early career launches which stand out for Peyton.

9:37 – The evolution of biologics.

15:30 – The history of the hub industry.

20:33 – How legislation and the government has influenced the overall industry.

22:19 – The consolidation of major players.

23:23 – What are we seeing in the industry today?

26:02 – Peyton’s advice for the future of the podcast.

27:42 – How copays have evolved.

32:47 – Areas of hope in the industry today.

34:!9 – Peyton’s prescription for better access.

Links:

Learn more about Dr. Scott Howell.

Learn more about Mark Hansan.

Comments or suggestions for Mark or Scott: comments@prescriptionforbetteraccess.com

Learn more about Peyton Howell.

Related Episodes

November 3, 2026

40. Understanding ICER’s Second Annual Launch Price and Access Report

In this episode, we welcome back Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER), to discuss an exciting new development in the industry: the release of ICER’s second annual Launch Price and Access Report. We dig into the report’s findings and explore why median net launch prices have climbed over the past several years, what the data show about delays and cost sharing for patients trying to get newly approved drugs, and what manufacturers, payers, and employers could do differently. Sarah makes the case for a voluntary de-escalation, with prices set in line with value and met by streamlined access. We also explore the role of purchasers, her call for a federally funded consortium of independent assessment groups, and her concerns about MFN.

 

Questions or comments? Email comments@prescriptionforbetteraccess.com. Find us on X, LinkedIn, YouTube, and Threads.

July 30, 2026

38. An Interview with Kathryn Carey, President, Optum Rx Pharmacy Benefit Manager

In this episode, we sit down with Kathryn Carey, President, Optum Rx Pharmacy Benefit Manager, to discuss one of the most significant shifts underway in the pharmacy benefit management industry. We explore their new transparent, fixed-fee model, what is driving it, and what it actually means for patients, providers, pharmacies, and manufacturers. We also examine Optum Rx’s digital tools and how they are reshaping the prescribing experience, and the broader effort to reduce friction in patient access. At its core, this is a conversation about whether these changes are early stages of a new model for how medicines are accessed and paid for in the United States.

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

May 20, 2026

37. Inside PhRMA: An Interview with Stephen Ubl, President and CEO, PhRMA

In this episode, we interview Stephen Ubl, President and CEO of PhRMA, to discuss what is happening across the industry at a time of significant change. We talk about biopharma’s continued commitment to innovation, what member companies are doing to help patients access medicines more directly, and how new tools from the organization are supporting patient affordability. We also cover the impact of policies like the IRA and MFN, along with the growing focus on PBM reform and other structural challenges in the system. It is a wide-ranging conversation about where the industry is headed and what it will take to ensure the country continues to lead the world in bringing new treatments to patients in need.

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

 

March 30, 2026

36. Spotlight on Rare Disease:  A Conversation with Alexander Hardy, President and CEO, BioMarin

In this episode, we sit down with Alexander Hardy, President and CEO of BioMarin, to talk about his career journey to become the leader of one of the world’s premier rare disease companies. Alexander reflects on his experience across small molecules, biologics, oncology, and rare diseases, and on how his work in access and patient services has shaped his thinking about leadership. We also discuss the policy environment coming out of Washington, including the IRA and other pricing reforms, and how those factors influence long-term innovation and investment decisions. Finally, we explore the real-world challenges facing rare disease patients, employer concerns about high-cost therapies, and what needs to change over the next five years to improve access and affordability.

Questions or comments?

Email us at comments@prescriptionforbetteraccess.com.Find us on social media: X, LinkedIn, YouTube, and Threads.

March 10, 2026

35. A Legal Perspective on PBM Reform and FTC Enforcement

In this episode of Prescription for Better Access, we’re joined by William (Bill) Sarraille, a leading legal expert on drug access and reimbursement, to unpack two major developments reshaping the pharmacy benefit landscape: the FTC’s recent enforcement action involving Express Scripts and the PBM reforms included in the Consolidated Appropriations Act of 2026. Bill helps translate what these policy and regulatory changes actually mean for benefit design, drug coverage, employer-sponsored plans, and transparency in the PBM market. We explore how these reforms may affect formularies, utilization management, contracting practices, and patient out-of-pocket costs—and where unintended consequences could emerge. The conversation cuts through the headlines to focus on the practical implications for employers, manufacturers, and, most importantly, patients seeking timely and affordable access to medicines.

Questions or comments?

Email us at comments@prescriptionforbetteraccess.com.Find us on social media: X, LinkedIn, YouTube, and Threads.

January 9, 2026

34. From Policy to the Employer Front Lines: A Conversation with Dan Mendelson of Morgan Health

Employers sit at the center of the U.S. health system as the primary funders of coverage for more than 150 million Americans, yet they struggle with rising costs, fragmented vendors, and uneven outcomes. In this episode, we talk with Dan Mendelson, MPP, CEO of Morgan Health at JPMorgan Chase & Co. and Founder and former CEO of Avalere Health. We explore his journey from health policy to now leading Morgan Health’s efforts to improve the quality, affordability and equity of employer-sponsored healthcare. We’ll learn how Morgan Health evaluates the employer market, where they’re placing investment bets, and how they are testing new care models inside JPMorgan’s own benefit. We then turn to Washington: Dan shares his take on the policy currents that matter most for employers and innovators over the next few years.
Questions or comments?Email us at comments@prescriptionforbetteraccess.com.Find us on social media: X, LinkedIn, YouTube, and Threads.
November 27, 2025

33. Understanding the Impact of the Accelerated Approvals Program

The FDA’s Accelerated Approval Program (AAP) aims to bring promising, potentially life-saving medicines to patients sooner by allowing approvals based on surrogate endpoints while requiring timely confirmatory evidence. In this episode, we speak with Bridget Doherty, MPH, MS (Johnson & Johnson Innovative Medicine), and Jeff Allen, PhD (Friends of Cancer Research). Bridget discusses her team’s review of the AAP’s real-world impact, showing that hundreds of thousands of meaningful life-years have been gained for patients. Jeff shares findings from work strengthening biomarkers as reliable surrogate endpoints—helping define when increased speed can still preserve scientific rigor. We also explore the core access challenge: how payer coverage and utilization management help or hinder patients the AAP is designed to serve. We close with practical policy steps to ensure that earlier regulatory access truly leads to better outcomes for people who need treatments most.

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media: X, LinkedIn, YouTube, and Threads.

Scroll to Top